Denver Health receives $5M grant to study CRE ‘superbug’

The National Institutes of Health has awarded a five year, $5 million grant to the Denver Health Medical Center and Accelerate Diagnostics, an in-vitro diagnostics company, to study the antibiotic-resistant ‘superbug’ known as carbapenem-resistant Enterobacteriaceae.

Advertisement

CRE is responsible for two recent infection outbreaks, one at Virginia Mason Medical Center in Seattle and another at Ronald Reagan UCLA Medical Center in Los Angeles.

The grant will support research by Denver Health and Accelerate Diagnostics as the two organizations work together to develop a fast, reliable blood test to detect the bacteria in less than three hours.

In addition to detecting the virus, Denver Health hopes to detect antibiotic susceptibility, according to one of the principal investigators on the study Connie Savor Price, MD.

“Accurate and timely detection would allow physicians to make better treatment choices and informed infection prevention measures to prevent further spread of the infection,” said Dr. Price. “That, in turn, would prevent the need for more antibiotic use — which is needed to stop feeding the vicious cycle of antimicrobial resistance.”

 

 

More articles on CRE:
FDA issues alert about scopes tied to CRE infections
5 things to know about the hospital ‘superbug’ outbreak at UCLA
enator pushes for FDA action on scopes that led to infections at Virginia Mason

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.